Will Hemp-Derived CBD Be Fully Legal with Passage of the 2018 Farm Bill? Not Quite…

by Wilson Elser
Contact

Wilson Elser

Public interest in the potential health benefits of CBD (cannabidiol) is responsible for a whole new market segment of health and wellness foods and supplements that features CBD as an ingredient. CBD is one of more than 100 cannabinoids in the cannabis plant, but unlike THC (tetrahydrocannabinol), CBD is not psychoactive and won’t get the user “high.” The CBD market is expected to top $591 million this year, and with federal protections could grow to $22 billion by 2022. Fueling this trend is scientific and anecdotal evidence of CBD’s effect on anxiety, pain, inflammation, nausea and seizures, as well as its value in fighting the opioid crisis. 

Given this intense interest, the Wilson Elser Cannabis Law practice team receives daily calls from people who want to know, “Is CBD legal?” Most who have sought this answer online find overly simplistic conclusions or, worse, legal advice that is dangerously wrong. When considering the legality of CBD, one must ask two equally important questions: Is CBD legal under the Controlled Substances Act (CSA)? Is CBD legal under U.S. food and drug laws? Most people tend to focus on the former due to media coverage on the evolving legal protections at the federal level, including new protections for hemp-derived CBD that are now confirmed to be included in the 2018 Farm Bill. Though not as sexy as the CSA, the Federal Food, Drug, and Cosmetic Act (FTCA) very likely presents the greater long-term problem for the CBD industry because there are few available protections to the legal risks presented by the FTCA. 

To appreciate the impact of the 2018 Farm Bill on the legality of hemp-derived CBD, it is necessary first to address the current legal landscape and relevant federal agencies. 

Marijuana versus Industrial Hemp
Under federal law, marijuana is a Schedule I controlled substance and illegal for any reason. The CSA defines marijuana as “all parts of the plant Cannabis sativa L − and every compound, manufacture, salt, derivative, mixture or preparation of such plant, its seeds or resin.” 

Industrial hemp is a subspecies of cannabis characterized by fibrous stalks and very low levels of THC. It is an agricultural commodity with many uses and was widely grown throughout human history as a cash crop until the 1920s when various states and eventually the federal government made all forms of marijuana illegal. After years of debate, in 2014 via the federal Farm Bill, Congress authorized state pilot programs to study the cultivation of and commercial market for industrial hemp as a viable agricultural crop. The Farm Bill’s definition of industrial hemp includes any part of the plant, including the flower. Unlike the CSA, the 2014 Farm Bill distinguished industrial hemp from marijuana based on the concentration of THC contained in each species. The currently accepted legal definition of industrial hemp is any part of the cannabis plant that has no more than 0.3 percent of THC on a dry weight basis. 

Cannabis is therefore regulated by the federal government within three broad categories, including (1) marijuana regulated under the CSA, (2) exempted parts of the cannabis plant under the CSA and (3) industrial hemp under the Farm Bills. Whether CBD is classified as a controlled substance is based primarily on the part of the plant from which the CBD is derived and whether it is derived from hemp as authorized by the Farm Bill. If CBD is derived from marijuana, it falls within Schedule I of the CSA, but if it is derived from properly sourced industrial hemp, it should fall outside the CSA. 

The 2018 Farm Bill
A major turning point for industrial hemp came in April 2018 with the introduction of Senate Majority Leader Mitch McConnell’s Hemp Farming Act of 2018 (HFA). Senator McConnell, a hemp advocate from Kentucky, later decided that the HFA would have a better chance of passage within the 2018 Farm Bill rather than as an independent bill. A companion bill also was introduced in the House of Representatives. After approval and reconciliation by the Senate and House, the final language within the 2018 Farm Bill will make drastic changes to the current laws concerning industrial hemp. It repeals section 7606 of the Agricultural Act within the 2014 Farm Bill, which mandated that hemp be grown under the auspices of a state agricultural pilot program or institution of higher education. It also removes industrial hemp from the CSA’s definition of “marijuana” and from Schedule I.

The 2018 Farm Bill should end the debate over the legal status of the plant under the CSA. All products made from industrial hemp, including CBD oil, will be legal under the CSA if they contain no more than 0.3 percent THC. State agriculture departments and Native American tribes will be free to regulate hemp in the same manner that any other agricultural commodity is regulated. The 2018 Farm Bill also should end the debate on the extent to which private businesses are allowed to engage in the commercial sales of products derived from industrial hemp, and whether hemp-derived products may be sold through interstate commerce into states that do not have industrial hemp agricultural pilot programs. The Drug Enforcement Agency (DEA) has consistently taken the position that this commercial activity was impermissible under the 2014 Farm Bill. It is hard to see how the DEA will have a legal basis to make this argument given the language of the 2018 Farm Bill. 

With broad federal protections for industrial hemp−derived products to be in place soon, we turn our attention to the legality of CBD under U.S. food and drug laws. 

The FDA and CBD
The U.S. Food and Drug Administration (FDA) is responsible for protecting the public health by ensuring the safety and efficacy of drugs and medical devices and the safety of the nation’s food supply. The FDCA forbids adulterated or misbranded food and drugs from entering into interstate commerce. It is the FDA’s position that all cannabinoids, including CBD, are impermissible additives that adulterate food and supplements for both humans and animals. The FDA does not differentiate the source of CBD – whether derived from cannabis or hemp – but rather considers all CBD to be an illegal food ingredient, regardless of source. 

Since 2015, the FDA has sent a number of letters to companies that sell CBD-infused oils and food products in interstate commerce, warning against making impermissible health claims. In the warning letters, the most recent of which is dated July 31, 2018, the FDA states that CBD products are in fact drugs, and not dietary supplements, under the FDCA because they are intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease and/or because they are intended to affect the structure or any function of the body. Accordingly, the “drugs” require FDA approval under the FDCA. 

The FDA also concludes that CBD products are not dietary supplements under the Dietary Supplement Health and Education Act (DSHEA). Under DSHEA, dietary ingredients marketed in the United States prior to October 15, 1994, may be used in dietary supplements without notification to the FDA, but new dietary ingredients cannot be used without a new dietary ingredient notification that provides the FDA with evidence establishing that the ingredient is “reasonably expected to be safe.” The FDA has concluded that CBD does not fall within the definition of a dietary ingredient because the FDA had previously authorized CBD for investigation as a new drug, for which substantial clinical research already had been conducted and made public. This is called Investigational New Drug Preclusion, or IND Preclusion. The FDA cites Epidiolex® and Sativex® as examples of clinical investigations regarding CBD that have been made public, beginning in 2006. 

There has been some discussion as to whether the FDA’s position on IND Preclusion may be challenged on the basis that CBD products were sold in interstate commerce prior to the publication of substantial clinical investigations of CBD. No formal challenge has been made to date, however. 

Another obstacle to the legal status of CBD under FDCA is the refusal of FDA to recognize CBD as “Generally Recognized as Safe” (GRAS), which is required of all food additives. Although GRAS determination has been made in the case of hemp seed oil, the FDA concludes that further research is needed for CBD. Future GRAS applications certainly will be made for CBD, but this must be done in accordance with the scientific process and will take time. 

In the meantime, the FDA has made clear that it still considers CBD unlawful in foods and supplements. In early November 2018, FDA’s Director of Dietary Supplement Programs is reported to have stated at a conference that “just because we haven’t taken enforcement action, people seem to think [CBD] is OK. [But] anyone who thinks it is lawful is mistaken.” 

Epidiolex
In June 2018, the FDA approved the first CBD-based drug, Epidiolex, for treatment of childhood seizures associated with two rare forms of epilepsy. In its June 25 press release, the FDA states: “CBD is currently a Schedule I substance because it is a chemical component of the cannabis plant.” By definition, a Schedule I substance has no accepted medical use. To resolve this conflict, in September 2018 the DEA rescheduled Epidiolex to Schedule V, the least restrictive schedule under the CSA. That action by the DEA only applies to Epidiolex and not to CBD generally. 

Many commentators have argued that the FDA misses the mark by making the broad statement that CBD is a Schedule 1 substance under the CSA “because it is a chemical component of the cannabis plant.” Despite conflicting statements by the DEA, the Farm Bills establish that CBD is a controlled substance only if it is derived from non-exempted parts of the marijuana plant, but it should not be a controlled substance if it is derived from industrial hemp. The Ninth Circuit has confirmed that the Farm Bills preempt and supersede the CSA. 

Unfortunately for those who want to capitalize on the booming demand for hemp-derived CBD food and supplement products, this is largely a distinction without a difference and underscores the new regulatory hurdles for federal approval of cannabis- and hemp-based products. Regardless of the source of CBD, the FDA has concluded that CBD is a drug with a real health benefit that is used to treat certain epileptic seizures and is being investigated for other medical uses. Because the FDA has made this determination, CBD cannot be freely added to food or supplements that are sold to the public. 

In sum, though the FDA’s recent approval of Epidiolex has been widely viewed as a positive development by those who want to see a change to the federal scheduling of marijuana, it has unexpectedly hamstrung the fledgling market for hemp-derived CBD products that are in high demand, including when used to fight the opioid crisis. 

CBD and State Regulations
Numerous states recently have weighed in on the legality of adding CBD or hemp to foods under state law. While states regulate food alongside and in cooperation with the FDA, states are responsible for food safety within state borders while the FDA’s mandate is to regulate interstate food and drug safety. We caution, however, that regardless of whether a state has taken a specific position on the issue, all states are obligated to refrain from enacting state food and drug laws that directly conflict with FDA regulations. 

California’s Announcement on CBD Sets off Alarms
On July 6, 2018, in response to numerous inquiries from CBD industry stakeholders and members of the public, the California Department of Public Health (CDPH) issued a public statement that CBD sourced from industrial hemp cannot be used in food in California. The CDPH relies on the FDA’s position, explaining: “California incorporates federal law regarding food additives, dietary use products, food labeling, and good manufacturing practices for food,” and that the “FDA has concluded that it is a prohibited act to introduce or deliver for introduction into interstate commerce any food (including any animal food or feed) to which THC or CBD has been added … regardless of the source of the CBD – derived from industrial hemp or cannabis.” 

The CDPH distinguishes CDB added to medicinal and adult-use “manufactured cannabis products,” including cannabis edibles, which are regulated by the CDPH Manufactured Cannabis Safety Branch. It explains that “although California currently allows the manufacturing and sales of cannabis products (including edibles), the use of industrial hemp as the source of CBD to be added to food products is prohibited.” Therefore, California takes the position that CBD sourced from marijuana is permitted in food products but is considered a cannabis product that only may be sold by retailers properly licensed under state cannabis regulations. On the other hand, CBD sourced from industrial hemp is not permitted in any food product under any condition. 

California’s public statement set off alarms within the CBD and hemp industries, and it precipitated several other states to make their own statements on the issue. 

Other States Weigh In
Several other states have recently clarified their respective positions on CBD under state law, though most do not distinguish between CBD that is derived from hemp versus marijuana. Many states do have exemptions under controlled substances state laws that mirror federal exemptions under the CSA. 

Alabama: Guidance recently released by the state’s attorney general makes clear that “all CBD is illegal under Alabama law, except for the prescription drug Epidiolex.” 

Alaska: In a September 2018 email, the state's Department of Environmental Conservation wrote "there are no lawfully approved sources of CBD" available in Alaska. As a result, the substance cannot be sold or used in permitted food establishments. 

Arizona: Arizona has a medical marijuana program, but state law enforcement has interpreted the law to exclude cannabis extracts, including CBD. There is a dispute heading to the state's Supreme Court. 

Colorado: Colorado’s House Bill 19-1295, which was signed into law in May 2018, modifies the Colorado Food and Drug Act to make explicit that food and drugs containing industrial hemp are not adulterated or misbranded under state law, under certain conditions. 

Illinois: In late August 2018, Governor Rauner signed a bill legalizing industrial hemp. The bill legalizes the farming of industrial hemp for commercial, research or pilot programs. It also permits the use of industrial hemp in health food. 

Indiana: Indiana recently has passed legislation permitting the distribution and retail sale of “low-THC hemp extract.” 

Iowa: On August 17, 2018, the Iowa Department of Health issued a position statement on CBD, stating "it is the position of the Department that CBD products are not legal in the state of Iowa, with few exceptions.” One of the exceptions includes products produced and approved under Iowa's Medical Cannabidiol Act that contain less than 3% THC. 

Kansas: The Kansas legislature passed a bill in June 2018 that removed from the state’s controlled substances list any hemp products that do not contain THC. The industry has taken that to mean CBD oil is permitted so long as it contains zero THC. 

Kentucky: The definition of marijuana under Kentucky state law exempts hemp-derived CBD products. 

Michigan: The possession, purchase or sale of marijuana or any marijuana product, including CBD, must be done in compliance with the Michigan Medical Marijuana Act and Medical Marijuana Facilities Licensing Act. Any possession or transfer of industrial hemp must be done in compliance with Michigan's Industrial Hemp Research Act. The Act authorizes growing and cultivating of industrial hemp for research purposes only and does not authorize its sale or transfer. 

Minnesota: Though Minnesota has little to no regulation of industrial hemp−derived CBD, the Minnesota Board of Pharmacy warns that the industry is too liberally interpreting the law. In an October 2018 article, Executive Director Cody Wiberg said, "I've sometimes characterized this as the Wild, Wild West. This is a very rapidly developing industry. There is actually very little regulation of it. The sellers will say this is a dietary supplement, the FDA has actually said no." Wiberg also said "we don't think they're legal right now," and he has urged caution among consumers. 

Missouri: In September 2018, the Missouri Department of Agriculture stated that "the legality of CBD oil is currently under review,” and that “we don't want to make any premature legal interpretations because of the impacts the federal Farm Bill may have."  

Montana: Under Montana's Hemp Pilot Program, approved products include alcoholic beverages, including beer and distilled and infused spirits, and cannabinoid oils, including CBD for food, cosmetic and health products. 

Nebraska: On November 16, 2018, the Nebraska Attorney General reminded sellers within the state that his office believes CBD is illegal. He has issued a memo to law enforcement stating that CBD remains illegal to possess, manufacture, distribute or dispense. 

New York: New York has a robust industrial hemp pilot program regulated by the state’s Department of Agriculture and Markets. Although the department hasn't explicitly permitted CBD-infused foods, it has a sample “CBD Research Partner Agreement” on its website that may be interpreted to imply that those licensed to grow industrial hemp can add CBD to food products. 

Ohio: In August 2018, the Ohio Board of Pharmacy issued a FAQ stating that CBD oil derived from hemp has always been illegal, and that CBD is legal only when extracted and sold through the state's medical marijuana program. The FAQ cites the DEA's reasoning that cannabinoids such as CBD are found in trace amounts only on the exempt parts of the plant. 

Tennessee: In 2014, Tennessee removed industrial hemp from the definition of marijuana in the state criminal code. In a February 2018 raid dubbed “Operation Candy Crush,” deputies from Rutherford County, Tennessee, closed approximately 25 retail stores and charged the owners for selling gummies made with CBD oil. All charges were later dropped, however, on the grounds that testing by the state could not distinguish if the oil came from marijuana or industrial hemp. After Candy Crush, state officials stated that the burden of proving CBD oil is not from hemp is on the state, not the accused. 

Texas: Although Texas initially considered issuing draft guidance that would bar the sale of CBD-infused products, the state has refrained from issuing guidance while it reevaluates its position. 

Washington: Washington allows licensed marijuana producers to use CBD from a source not licensed by the state’s Liquor and Cannabis Board, so long as the CBD product has a THC level of 0.3 percent or less on a dry weight basis and has been lab tested. 

Wisconsin: In May 2018, the state issued a report concluding that the sale of CBD was illegal under state and federal law. The state Attorney General (AG) issued a statement that “law enforcement has encountered examples of products claiming to be CBD oil that resulted in people getting hurt and sick.” Shortly thereafter, however, the AG backtracked and confirmed that products made from industrial hemp are lawful, including hemp-derived CBD. The AG’s memo explains: “With the 2018 Farm Bill now working its way through Congress, it is likely that our current laws will be changed even further to make industrial hemp's legality clear. Therefore, I am advising law enforcement not to take enforcement action against products made from industrial hemp that is grown under a lawful hemp research pilot program, including CBD, until Congress considers changes to the law, enabling the Wisconsin State Legislature to further clarify the status of these products.” Stores are currently permitted to sell CBD oil produced in compliance with state regulations. 

An Absurd Result
These federal and state positions have created an absurd result. CBD now may be manufactured and distributed in many states with few restrictions but CBD may be added to food products in many states only if it is derived from marijuana. It is difficult to logically reconcile this “schizophrenic” state of the law. Although the FDA has always prohibited cannabinoids in food, it has to date only taken enforcement action when CBD products making health claims were sold online or were otherwise introduced into interstate commerce. It remains to be seen what position will be taken by the FDA when cannabis edible products are able to move in interstate commerce, thus triggering the FDA’s jurisdiction. 

Evaluating the Risk
Some who sell hemp-derived CBD products may be tempted to keep moving forward and hope for the best. After all, that’s basically what the cannabis industry did vis-à-vis the DOJ and DEA in the face of federal illegality, and the FDA has remained largely on the sidelines when it comes to CBD because, until recently, few CBD products have been available in interstate commerce. Despite its July 2018 statement, California’s Department of Public Health has not yet taken any visible enforcement action on non-cannabis CBD. 

Many may therefore ask what risk there is in simply continuing to sell their products. It is tempting to focus on potential regulatory enforcement action as the greatest risk, including from recalls, seizures, injunctions and civil penalties. Tort exposure to civil lawsuits, however, is likely the larger problem. Unlike selling federally illegal cannabis products pursuant to a state-regulated market where participants are protected under state laws, no such protection exists for sellers of CBD products that are considered adulterated and misbranded under both federal and state law. Even in states that allow CBD in food products, or in states that have not yet announced a formal position, the FDA’s prohibition may be enough for the determination by a jury that such products are illegally adulterated and misbranded, particularly if the CBD product is being sold in interstate commerce. 

Most states have consumer protection laws that provide statutory remedies against companies that sell adulterated, mislabeled, misbranded or contaminated products. Those statutes may provide the basis for consumer class actions brought against companies that sell allegedly adulterated or misbranded food products containing CBD. Importantly, insurance companies often decline coverage for these claims, leaving the company to fend for itself. Uninsured losses arising out of similar consumer class actions have proven problematic for the dietary supplement industry for many years. 

Meanwhile, class-action attorneys will be on the hunt for impermissible claims or the marketing of ingredients not approved by the FDA. Products must be labeled accurately, or they are in violation of federal and state law. Health claims must be avoided for foods and beverages that cannot claim to treat, cure or diagnose a disease. Any company that markets a dietary supplement must have adequate substantiation for any health claim made. CBD stakeholders also should be on the alert for contamination claims. Even trace amounts of THC in a hemp-derived CBD product can potentially form the basis of substantial liability, and especially if not properly disclosed on the product label. 

Ultimately, the new federal protections contained in the 2018 Farm Bill will move the CBD-based food and supplement industry closer to unrestricted national and international distribution of hemp-derived CBD products. Until approved by the FDA, however, CBD as an ingredient in foods and supplements will continue to be risky. That approval process within the FDA may take months or, more likely, years. In the meantime, it is ironic that removal of the DOJ and DEA’s authority over hemp-derived CBD will pave the way for the stepped-up jurisdiction and enforcement by the FDA, and a heightened risk of civil lawsuits as CBD enters the mainstream.

DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Wilson Elser | Attorney Advertising

Written by:

Wilson Elser
Contact
more
less

Wilson Elser on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide

JD Supra Privacy Policy

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Collection of Information

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

  • Email
  • First Name
  • Last Name
  • Company Name
  • Company Industry
  • Title
  • Country

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

How do we use this information?

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

  • Operate our Website and Services and publish content;
  • Distribute content to you in accordance with your preferences as well as to provide other notifications to you (for example, updates about our policies and terms);
  • Measure readership and usage of the Website and Services;
  • Communicate with you regarding your questions and requests;
  • Authenticate users and to provide for the safety and security of our Website and Services;
  • Conduct research and similar activities to improve our Website and Services; and
  • Comply with our legal and regulatory responsibilities and to enforce our rights.

How is your information shared?

  • Content and other public information (such as an author profile) is shared on our Website and Services, including via email digests and social media feeds, and is accessible to the general public.
  • If you choose to use our Website and Services to communicate directly with a company or individual, such communication may be shared accordingly.
  • Readership information is provided to publishing law firms and authors of content to give them insight into their readership and to help them to improve their content.
  • Our Website may offer you the opportunity to share information through our Website, such as through Facebook's "Like" or Twitter's "Tweet" button. We offer this functionality to help generate interest in our Website and content and to permit you to recommend content to your contacts. You should be aware that sharing through such functionality may result in information being collected by the applicable social media network and possibly being made publicly available (for example, through a search engine). Any such information collection would be subject to such third party social media network's privacy policy.
  • Your information may also be shared to parties who support our business, such as professional advisors as well as web-hosting providers, analytics providers and other information technology providers.
  • Any court, governmental authority, law enforcement agency or other third party where we believe disclosure is necessary to comply with a legal or regulatory obligation, or otherwise to protect our rights, the rights of any third party or individuals' personal safety, or to detect, prevent, or otherwise address fraud, security or safety issues.
  • To our affiliated entities and in connection with the sale, assignment or other transfer of our company or our business.

How We Protect Your Information

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Children's Information

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Links to Other Websites

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

Information for EU and Swiss Residents

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

  • Our Legal Basis for Processing: Generally, we rely on our legitimate interests in order to process your personal information. For example, we rely on this legal ground if we use your personal information to manage your Registration Data and administer our relationship with you; to deliver our Website and Services; understand and improve our Website and Services; report reader analytics to our authors; to personalize your experience on our Website and Services; and where necessary to protect or defend our or another's rights or property, or to detect, prevent, or otherwise address fraud, security, safety or privacy issues. Please see Article 6(1)(f) of the E.U. General Data Protection Regulation ("GDPR") In addition, there may be other situations where other grounds for processing may exist, such as where processing is a result of legal requirements (GDPR Article 6(1)(c)) or for reasons of public interest (GDPR Article 6(1)(e)). Please see the "Your Rights" section of this Privacy Policy immediately below for more information about how you may request that we limit or refrain from processing your personal information.
  • Your Rights
    • Right of Access/Portability: You can ask to review details about the information we hold about you and how that information has been used and disclosed. Note that we may request to verify your identification before fulfilling your request. You can also request that your personal information is provided to you in a commonly used electronic format so that you can share it with other organizations.
    • Right to Correct Information: You may ask that we make corrections to any information we hold, if you believe such correction to be necessary.
    • Right to Restrict Our Processing or Erasure of Information: You also have the right in certain circumstances to ask us to restrict processing of your personal information or to erase your personal information. Where you have consented to our use of your personal information, you can withdraw your consent at any time.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

  • Timeframe for retaining your personal information: We will retain your personal information in a form that identifies you only for as long as it serves the purpose(s) for which it was initially collected as stated in this Privacy Policy, or subsequently authorized. We may continue processing your personal information for longer periods, but only for the time and to the extent such processing reasonably serves the purposes of archiving in the public interest, journalism, literature and art, scientific or historical research and statistical analysis, and subject to the protection of this Privacy Policy. For example, if you are an author, your personal information may continue to be published in connection with your article indefinitely. When we have no ongoing legitimate business need to process your personal information, we will either delete or anonymize it, or, if this is not possible (for example, because your personal information has been stored in backup archives), then we will securely store your personal information and isolate it from any further processing until deletion is possible.
  • Onward Transfer to Third Parties: As noted in the "How We Share Your Data" Section above, JD Supra may share your information with third parties. When JD Supra discloses your personal information to third parties, we have ensured that such third parties have either certified under the EU-U.S. or Swiss Privacy Shield Framework and will process all personal data received from EU member states/Switzerland in reliance on the applicable Privacy Shield Framework or that they have been subjected to strict contractual provisions in their contract with us to guarantee an adequate level of data protection for your data.

California Privacy Rights

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Privacy Officer
JD Supra, LLC
10 Liberty Ship Way, Suite 300
Sausalito, California 94965

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

Access/Correct/Update/Delete Personal Information

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

Changes in Our Privacy Policy

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

Contacting JD Supra

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

JD Supra Cookie Guide

As with many websites, JD Supra's website (located at www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

How We Use Cookies and Other Tracking Technologies

We use cookies and other tracking technologies to:

  1. Improve the user experience on our Website and Services;
  2. Store the authorization token that users receive when they login to the private areas of our Website. This token is specific to a user's login session and requires a valid username and password to obtain. It is required to access the user's profile information, subscriptions, and analytics;
  3. Track anonymous site usage; and
  4. Permit connectivity with social media networks to permit content sharing.

There are different types of cookies and other technologies used our Website, notably:

  • "Session cookies" - These cookies only last as long as your online session, and disappear from your computer or device when you close your browser (like Internet Explorer, Google Chrome or Safari).
  • "Persistent cookies" - These cookies stay on your computer or device after your browser has been closed and last for a time specified in the cookie. We use persistent cookies when we need to know who you are for more than one browsing session. For example, we use them to remember your preferences for the next time you visit.
  • "Web Beacons/Pixels" - Some of our web pages and emails may also contain small electronic images known as web beacons, clear GIFs or single-pixel GIFs. These images are placed on a web page or email and typically work in conjunction with cookies to collect data. We use these images to identify our users and user behavior, such as counting the number of users who have visited a web page or acted upon one of our email digests.

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

  • HubSpot - For more information about HubSpot cookies, please visit legal.hubspot.com/privacy-policy.
  • New Relic - For more information on New Relic cookies, please visit www.newrelic.com/privacy.
  • Google Analytics - For more information on Google Analytics cookies, visit www.google.com/policies. To opt-out of being tracked by Google Analytics across all websites visit http://tools.google.com/dlpage/gaoptout. This will allow you to download and install a Google Analytics cookie-free web browser.

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

Controlling and Deleting Cookies

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

Updates to This Policy

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

Contacting JD Supra

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.